Going green is no longer a gimmick, and there is money to be made. However, what are the challenges for the industry moving forward? What will ultimately be a competitive advantage for pharma companies and supply chain stakeholders in the next 10 years?

The majority of the world is realizing that burning fossil fuels is no longer a “free for all” game, and that we need to start moving towards alternative energy sources sooner than later or face disastrous consequences for our environment. More importantly, regulators around the world have started to clamp down on traditional ‘dirty’ sources of energy.

This provocative session will explore how both pharma companies and the their supply chain partners will need to start exploring alternative transportation, and push 3PLs and other shippers to start addressing the fact that moving around trillions of tons of goods without reducing emissions might soon become unsustainable.

Presentation by Eugenio Filippi,  Head of Manufacturing, Vienna, Austria Takeda Pharmaceuticals Company Limited

Implementing technical data and authenticating the life history of a product can improve supply chain security and streamline processes. Eli Lilly is using an effective stability budget for unplanned excursions and testing the capability of a product that is shipped around the world across a multitude of suppliers, regulations and patients.

• Model statistics around the analytical methods
• Piece together the time and temperature allowed outside the label claim
• Leverage capability to ship products around the world
• Discovering the limits of time and beating the expectation
• Discuss the global perspectives on stability budgets and impacts on supply chain products

Presentation by K. Nicole Harter Consultant Quality Assurance – Global Marketing Affiliates and Global Logistics Eli Lilly and Company

Eli Lilly partners with AeroSafe Global to Reduce their Cold Chain Total Cost of Ownership When considering a cold chain packaging partner, Eli Lilly demonstrates how including operations, warehouse, logistics and compliance costs in the Total Cost of Ownership results is a more responsible approach. In utilizing AeroSafe Global’s “Cold Chain as a Service”, Eli Lilly was able to benefit from the highest performing solutions while simultaneously reducing costs and improving sustainability.

• Challenges with previous shipper system
• Qualification and selection process for new shipping systems
• Quantify significant cost savings derived from multiple operational efficiencies

Presentation by Christopher C. Lyons,  Consultant Engineer,  Eli Lilly and Company and Mike Mondo VP, Sales ,Aerosafe Global

Blockchain will provide an excellent framework and foundation to give the end to end visibility with the highest level of trust. Within a closed blockchain, everyone that is part of the blockchain will have total visibility throughout the blocks. If any data happens to change, immediate visibility will be available in the distributed ledger.

• Improve the visibility and “trust” of all partners within the closed blockchain 
• Enhance safety because of the ability of the blockchain (through cryptology) to maintain total integrity and accuracy of data
• Address the growing concern on the electrical grid being able to manage all the blockchains that will evolve

Presentation by Dean Croke Board Member Blockchain in Transportation Alliance (BiTA)

AstraZeneca recently set up a global logistics function including process control and a Center of Excellence. Learn about the company’s journey and their future plans for 2025.

• Merging two types of businesses into one global function
• Establishing future direction for all of the global logistics functions
• Addressing issues arising with a changing portfolio
• Shifting from high volume, low value to high value, low volume products.

Presentation by Mark Everitt, CSCP Qualification Engineer, AstraZeneca Pharmaceuticals